Ocushield: Blue Light Blocking Filters in the Eye Care Practice

Apr 29, 2022

In this episode, Dhruvin Patel, MCOptom, discusses the short- and long-term effects of blue light on our eyes, how the pandemic has exacerbated these effects and how his company, Ocushield, is looking to help protect eyes from blue light.

• Intro :01
• Patel’s introduction and background :43
• The science and necessity behind blue light blocking filters 5:35
• Short-term effects of blue light on the eyes 7:15
• Long-term effects of blue light on the eyes 8:24
• Are eye care professionals doing enough to promote blue light protection? 12:11
• Has the pandemic affected the demand/awareness of blue light related products? 14:25
• Ocushield filters: what they are and how to get them 16:15
• What makes Ocushield unique in the blue light/ophthalmic landscape? 19:03
• How to contact Dr. Patel and Ocushield 20:31
• Patel’s final thoughts on our visual system and the importance of protecting it 21:11
• Outro 22:01

Dhruvin Patel, MCOptom, is an optometrist and the founder of Ocushield. You can send your comments/questions directly to him at www.ocushield.com.  Follow him on Instagram, Facebook and Twitter @getocushield.

We’d love to hear from you! Send your comments/questions to Dr. Mali at [e-mail]. Follow us on Twitter @Healio_OSN

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Patel is founder of Ocushield.